1. Short title This Act may be cited as the Access to Rare Indications Act of 2020 . 2. Coverage of certain drugs used in treatment or management of rare disease or condition (a) Medicare (1) In general Section 1861(t)(2) of the Social Security Act ( 42 U.S.C. 1395x(t)(2) ) is amended— (A) in subparagraph (A), by inserting after regimen the following: , or in the treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States, ; and (B) in subparagraph (B)(ii)— (i) in subclause (I), by striking , or at the end and inserting a semicolon; (ii) in subclause (II), by striking the period at the end and inserting ; or ; and (iii) by adding at the end the following new subclause: (III) in the case that the drug is used in the treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States, such use is supported by peer-reviewed literature, clinical guidelines, or expert opinion within the National Institutes of Health Rare Diseases Clinical Research Network consortia or its participating clinical centers. . (2) Prohibition of coverage exclusions for formularies under Medicare part D Section 1860D–4(b)(3) of the Social Security Act ( 42 U.S.C. 1395w–104(b)(3) ) is amended by adding at the end the following new subparagraph: (I) Prohibition of certain coverage exclusions (i) In general If the PDP sponsor of a prescription drug plan uses a formulary, such sponsor may not impose a limitation or exclusion of benefits with respect to coverage of a rare disease covered part D drug (as defined in clause (ii)) included in such formulary. (ii) Rare disease covered part D drug For purposes of this subparagraph, the term rare disease covered part D drug means a covered part D drug— (I) used in the treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States